ACAD
ACADIA Pharmaceuticals Inc.
Price Chart
Latest Quote
$25.60
-0.03 (-0.12%)
Current Price
| Previous Close | $25.63 |
| Open | $25.37 |
| Day High | $25.84 |
| Day Low | $25.20 |
| Volume | 1,139,988 |
Stock Information
| Shares Outstanding | 171.24M |
| Total Debt | $50.79M |
| Cash Equivalents | $851.46M |
| Revenue | $1.10B |
| Net Income | $375.65M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.38B |
| P/E Ratio | 11.58 |
| EPS (TTM) | $2.21 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.58B |
| Sales | $1.10B |
| Income | $375.65M |
| Book/sh | $7.29 |
| Cash/sh | $4.97 |
| Employees | 796 |
Financial Ratios
| Quick Ratio | 3.27 |
| Current Ratio | 3.59 |
| Debt/Eq | 4.07 |
| EPS Growth TTM | -80.80% |
Returns & Margins
| ROA | 3.69% |
| ROE | 37.32% |
| Gross Margin | 61.58% |
| Operating Margin | -1.72% |
| Profit Margin | 34.30% |
Ownership
| Insider Ownership | 0.32% |
| Institutional Ownership | 98.91% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.74 |
| PEG | 50.86 |
| P/S | 4.00 |
| P/B | 3.51 |
Analyst Data
| Recommendation | buy |
| Target Price | $32.65 |
Technical Indicators
| SMA20 | $24.96 |
| SMA50 | $22.86 |
| SMA200 | $23.41 |
| RSI | 53.50 |
| ATR | 0.8093 |
| Shares Float | 127.19M |
| Short Float | 10.14% |
| Short Ratio | 6.56 |
| Volatility | 0.80 |
| Rel Volume | 0.62 |
Performance History
| Week | -2.36% |
| Month | +22.25% |
| Quarter | +20.47% |
| 6 Months | -4.69% |
| YTD | -2.62% |
| Year | +13.53% |
| 3 Years | -1.01% |
| 5 Years | +7.97% |
| 10 Years | -23.01% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $25.60 | 1,207,300 |
| 2026-07-16 | $25.63 | 2,189,300 |
| 2026-07-15 | $25.92 | 1,274,100 |
| 2026-07-14 | $25.49 | 1,221,000 |
| 2026-07-13 | $25.50 | 1,562,800 |
| 2026-07-10 | $26.22 | 1,442,800 |
| 2026-07-09 | $26.41 | 1,801,300 |
| 2026-07-08 | $26.00 | 1,551,900 |
| 2026-07-07 | $26.20 | 1,674,500 |
| 2026-07-06 | $25.77 | 1,155,000 |
| 2026-07-02 | $25.97 | 1,586,400 |
| 2026-07-01 | $25.20 | 1,417,700 |
| 2026-06-30 | $25.30 | 1,721,300 |
| 2026-06-29 | $25.20 | 2,090,000 |
| 2026-06-26 | $25.32 | 7,370,500 |
| 2026-06-25 | $23.72 | 1,491,600 |
| 2026-06-24 | $23.36 | 1,495,800 |
| 2026-06-23 | $22.60 | 1,476,900 |
| 2026-06-22 | $22.09 | 1,904,400 |
| 2026-06-18 | $21.62 | 3,225,600 |
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
đ° Latest News
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Motley Fool âĸ 2026-07-11T21:10:01Z
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?
Simply Wall St. âĸ 2026-07-11T02:09:48Z
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?
Simply Wall St. âĸ 2026-07-10T14:15:36Z
How CHMPâs Positive Rett Syndrome Ruling on DAYBU Could Impact ACADIA Pharmaceuticals (ACAD) Investors
Simply Wall St. âĸ 2026-07-10T13:12:41Z
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
Zacks âĸ 2026-07-10T09:45:00Z
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Zacks âĸ 2026-07-09T15:40:02Z
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Zacks âĸ 2026-06-29T15:15:00Z
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Zacks âĸ 2026-06-29T13:37:00Z
The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout
Investor's Business Daily âĸ 2026-06-26T20:24:26Z
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires âĸ 2026-06-26T19:42:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $88,998,000 | $81,841,000 | $41,638,000 | $10,166,000 |
| Cost Of Revenue | $88,998,000 | $81,841,000 | $41,638,000 | $10,166,000 |
| Total Revenue | $1,071,505,000 | $957,797,000 | $726,437,000 | $517,235,000 |
| Operating Revenue | $1,071,505,000 | $957,797,000 | $726,437,000 | $517,235,000 |
| Expenses | ||||
| Total Expenses | $966,694,000 | $873,518,000 | $799,816,000 | $740,831,000 |
| Other Income Expense | $2,371,000 | $148,338,000 | $5,109,000 | $3,542,000 |
| Other Non Operating Income Expenses | $2,371,000 | $1,823,000 | $5,109,000 | $3,542,000 |
| Net Non Operating Interest Income Expense | $31,722,000 | $25,458,000 | $17,234,000 | $6,610,000 |
| Operating Expense | $877,696,000 | $791,677,000 | $758,178,000 | $730,665,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Net Interest Income | $31,722,000 | $25,458,000 | $17,234,000 | $6,610,000 |
| Interest Income | $31,722,000 | $25,458,000 | $17,234,000 | $6,610,000 |
| Normalized Income | $391,000,000 | $97,889,658 | $-61,286,000 | $-215,975,000 |
| Net Income From Continuing And Discontinued Operation | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Total Operating Income As Reported | $104,811,000 | $230,794,000 | $-73,379,000 | $-223,596,000 |
| Net Income Common Stockholders | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Net Income | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Net Income Including Noncontrolling Interests | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Net Income Continuous Operations | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Pretax Income | $138,904,000 | $258,075,000 | $-51,036,000 | $-213,444,000 |
| Special Income Charges | $0 | $146,515,000 | $0 | $0 |
| Interest Income Non Operating | $31,722,000 | $25,458,000 | $17,234,000 | $6,610,000 |
| Operating Income | $104,811,000 | $84,279,000 | $-73,379,000 | $-223,596,000 |
| Gross Profit | $982,507,000 | $875,956,000 | $684,799,000 | $507,069,000 |
| Per Share | ||||
| Diluted EPS | $2.30 | $1.36 | $-0.37 | $-1.34 |
| Basic EPS | $2.32 | $1.37 | $-0.37 | $-1.34 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $17,953,658 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $116,571,000 | $-46,353,000 | $-67,827,000 | $-221,570,000 |
| Total Unusual Items | $0 | $146,515,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $146,515,000 | $0 | $0 |
| Reconciled Depreciation | $11,760,000 | $15,883,000 | $5,552,000 | $2,026,000 |
| EBITDA (Bullshit earnings) | $116,571,000 | $100,162,000 | $-67,827,000 | $-221,570,000 |
| EBIT | $104,811,000 | $84,279,000 | $-73,379,000 | $-223,596,000 |
| Diluted Average Shares | $169,919,000 | $166,362,000 | $163,819,000 | $161,683,000 |
| Basic Average Shares | $168,356,000 | $165,717,000 | $163,819,000 | $161,683,000 |
| Diluted NI Availto Com Stockholders | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Tax Provision | $-252,096,000 | $31,624,000 | $10,250,000 | $2,531,000 |
| Gain On Sale Of Ppe | $0 | $146,515,000 | $0 | $0 |
| Research And Development | $328,802,000 | $303,249,000 | $351,619,000 | $361,575,000 |
| Selling General And Administration | $548,894,000 | $488,428,000 | $406,559,000 | $369,090,000 |
| Other Gand A | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,118,497,000 | $613,011,000 | $366,265,000 | $400,413,000 |
| Total Assets | $1,564,195,000 | $1,187,756,000 | $748,956,000 | $587,812,000 |
| Total Non Current Assets | $502,082,000 | $249,438,000 | $132,831,000 | $79,875,000 |
| Other Non Current Assets | $88,445,000 | $78,870,000 | $10,874,000 | $18,281,000 |
| Non Current Deferred Assets | $249,879,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $249,879,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $108,893,000 | $119,782,000 | $65,490,000 | $0 |
| Current Assets | $1,062,113,000 | $938,318,000 | $616,125,000 | $507,937,000 |
| Prepaid Assets | $59,526,000 | $55,681,000 | $39,091,000 | $21,398,000 |
| Inventory | $34,670,000 | $21,949,000 | $35,819,000 | $6,636,000 |
| Receivables | $148,231,000 | $104,695,000 | $102,350,000 | $63,080,000 |
| Accrued Interest Receivable | $26,774,000 | $5,956,000 | $4,083,000 | $885,000 |
| Accounts Receivable | $121,457,000 | $98,739,000 | $98,267,000 | $62,195,000 |
| Cash Cash Equivalents And Short Term Investments | $819,686,000 | $755,993,000 | $438,865,000 | $416,823,000 |
| Cash And Cash Equivalents | $177,695,000 | $319,589,000 | $188,657,000 | $114,846,000 |
| Debt | ||||
| Total Debt | $52,187,000 | $51,995,000 | $57,205,000 | $62,000,000 |
| Long Term Debt And Capital Lease Obligation | $40,554,000 | $42,037,000 | $47,800,000 | $52,695,000 |
| Current Debt And Capital Lease Obligation | $11,633,000 | $9,958,000 | $9,405,000 | $9,305,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $336,805,000 | $454,963,000 | $317,201,000 | $187,399,000 |
| Total Non Current Liabilities Net Minority Interest | $59,691,000 | $60,093,000 | $62,947,000 | $61,769,000 |
| Other Non Current Liabilities | $19,137,000 | $18,056,000 | $15,147,000 | $9,074,000 |
| Current Liabilities | $277,114,000 | $394,870,000 | $254,254,000 | $125,630,000 |
| Payables And Accrued Expenses | $219,902,000 | $348,361,000 | $202,131,000 | $88,302,000 |
| Payables | $11,207,000 | $28,208,000 | $19,107,000 | $13,123,000 |
| Total Tax Payable | $304,000 | $12,016,000 | $1,564,000 | $377,000 |
| Accounts Payable | $10,903,000 | $16,192,000 | $17,543,000 | $12,746,000 |
| Equity | ||||
| Common Stock Equity | $1,227,390,000 | $732,793,000 | $431,755,000 | $400,413,000 |
| Total Equity Gross Minority Interest | $1,227,390,000 | $732,793,000 | $431,755,000 | $400,413,000 |
| Stockholders Equity | $1,227,390,000 | $732,793,000 | $431,755,000 | $400,413,000 |
| Gains Losses Not Affecting Retained Earnings | $1,445,000 | $292,000 | $24,000 | $-975,000 |
| Other Equity Adjustments | $1,445,000 | $292,000 | $24,000 | $-975,000 |
| Retained Earnings | $-1,813,386,000 | $-2,204,386,000 | $-2,430,837,000 | $-2,369,551,000 |
| Other | ||||
| Ordinary Shares Number | $170,309,376 | $166,708,856 | $164,650,219 | $162,064,872 |
| Share Issued | $170,309,376 | $166,708,856 | $164,650,219 | $162,064,872 |
| Tangible Book Value | $1,118,497,000 | $613,011,000 | $366,265,000 | $400,413,000 |
| Invested Capital | $1,227,390,000 | $732,793,000 | $431,755,000 | $400,413,000 |
| Working Capital | $784,999,000 | $543,448,000 | $361,871,000 | $382,307,000 |
| Capital Lease Obligations | $52,187,000 | $51,995,000 | $57,205,000 | $62,000,000 |
| Total Capitalization | $1,227,390,000 | $732,793,000 | $431,755,000 | $400,413,000 |
| Additional Paid In Capital | $3,039,315,000 | $2,936,871,000 | $2,862,552,000 | $2,770,923,000 |
| Capital Stock | $16,000 | $16,000 | $16,000 | $16,000 |
| Common Stock | $16,000 | $16,000 | $16,000 | $16,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $40,554,000 | $42,037,000 | $47,800,000 | $52,695,000 |
| Current Capital Lease Obligation | $11,633,000 | $9,958,000 | $9,405,000 | $9,305,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $45,579,000 | $36,551,000 | $42,718,000 | $28,023,000 |
| Current Accrued Expenses | $208,695,000 | $320,153,000 | $183,024,000 | $75,179,000 |
| Net PPE | $54,865,000 | $50,786,000 | $56,467,000 | $61,594,000 |
| Accumulated Depreciation | $-9,484,000 | $-10,217,000 | $-9,556,000 | $-8,097,000 |
| Gross PPE | $64,349,000 | $61,003,000 | $66,023,000 | $69,691,000 |
| Leases | $4,644,000 | $3,746,000 | $3,746,000 | $3,696,000 |
| Construction In Progress | $3,262,000 | $523,000 | $0 | - |
| Other Properties | $47,354,000 | $46,571,000 | $51,855,000 | $55,573,000 |
| Machinery Furniture Equipment | $9,089,000 | $10,163,000 | $10,422,000 | $10,422,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $641,991,000 | $436,404,000 | $250,208,000 | $301,977,000 |
| Finished Goods | - | - | - | $1,926,000 |
| Work In Process | - | - | - | $4,427,000 |
| Raw Materials | - | - | - | $283,000 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $105,146,000 | $157,196,000 | $16,652,000 | $-114,035,000 |
| Operating Activities | ||||
| Operating Cash Flow | $109,836,000 | $157,719,000 | $16,702,000 | $-114,035,000 |
| Cash Flow From Continuing Operating Activities | $109,836,000 | $157,719,000 | $16,702,000 | $-114,035,000 |
| Operating Gains Losses | - | $-146,515,000 | $-4,585,000 | $-3,542,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,690,000 | $-523,000 | $-50,000 | - |
| Investing Cash Flow | $-302,564,000 | $-30,538,000 | $31,998,000 | $73,241,000 |
| Cash Flow From Continuing Investing Activities | $-302,564,000 | $-30,538,000 | $31,998,000 | $73,241,000 |
| Net Other Investing Changes | - | $146,515,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $49,883,000 | $6,845,000 | $25,129,000 | $8,199,000 |
| Financing Cash Flow | $49,883,000 | $6,845,000 | $25,129,000 | $8,199,000 |
| Cash Flow From Continuing Financing Activities | $49,883,000 | $6,845,000 | $25,129,000 | $8,199,000 |
| Net Common Stock Issuance | $49,883,000 | $6,845,000 | $25,129,000 | $8,199,000 |
| Common Stock Issuance | $49,883,000 | $6,845,000 | $25,129,000 | $8,199,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $25,170,000 | $19,521,000 | $5,850,000 | $2,190,000 |
| End Cash Position | $185,540,000 | $328,359,000 | $194,427,000 | $120,616,000 |
| Beginning Cash Position | $328,359,000 | $194,427,000 | $120,616,000 | $153,205,000 |
| Effect Of Exchange Rate Changes | $26,000 | $-94,000 | $-18,000 | $6,000 |
| Changes In Cash | $-142,845,000 | $134,026,000 | $73,829,000 | $-32,595,000 |
| Net Investment Purchase And Sale | $-199,036,000 | $-176,530,000 | $72,048,000 | $73,241,000 |
| Sale Of Investment | $493,529,000 | $328,565,000 | $442,033,000 | $436,415,000 |
| Purchase Of Investment | $-692,565,000 | $-505,095,000 | $-369,985,000 | $-363,174,000 |
| Net Business Purchase And Sale | $-98,838,000 | $0 | $-40,000,000 | - |
| Purchase Of Business | $-98,838,000 | $0 | $-40,000,000 | - |
| Net PPE Purchase And Sale | $-4,690,000 | $-523,000 | $-50,000 | $0 |
| Purchase Of PPE | $-4,690,000 | $-523,000 | $-50,000 | $0 |
| Change In Working Capital | $-89,756,000 | $4,155,000 | $18,133,000 | $37,991,000 |
| Change In Other Current Liabilities | $-5,435,000 | $-4,689,000 | $201,000 | $-5,876,000 |
| Change In Other Current Assets | $5,811,000 | $7,619,000 | $5,736,000 | $6,518,000 |
| Change In Payables And Accrued Expense | $-24,554,000 | $69,710,000 | $97,967,000 | $30,176,000 |
| Change In Accrued Expense | $-19,265,000 | $71,061,000 | $93,170,000 | $24,306,000 |
| Change In Payable | $-5,289,000 | $-1,351,000 | $4,797,000 | $5,870,000 |
| Change In Account Payable | $-5,289,000 | $-1,351,000 | $4,797,000 | $5,870,000 |
| Change In Prepaid Assets | $-3,845,000 | $-16,590,000 | $-17,693,000 | $2,494,000 |
| Change In Inventory | $-18,197,000 | $-49,550,000 | $-28,808,000 | $2,415,000 |
| Change In Receivables | $-43,536,000 | $-2,345,000 | $-39,270,000 | $2,264,000 |
| Changes In Account Receivables | $-22,718,000 | $-472,000 | $-36,072,000 | $2,171,000 |
| Other Non Cash Items | $-249,879,000 | - | - | - |
| Stock Based Compensation | $52,135,000 | $67,049,000 | $66,421,000 | $68,201,000 |
| Amortization Of Securities | $-5,424,000 | $-9,304,000 | $-7,533,000 | $-2,736,000 |
| Depreciation Amortization Depletion | $11,760,000 | $15,883,000 | $5,552,000 | $2,026,000 |
| Depreciation And Amortization | $11,760,000 | $15,883,000 | $5,552,000 | $2,026,000 |
| Amortization Cash Flow | $10,889,000 | $14,963,000 | $4,093,000 | $0 |
| Amortization Of Intangibles | $10,889,000 | $14,963,000 | $4,093,000 | $0 |
| Depreciation | $871,000 | $920,000 | $1,459,000 | $2,026,000 |
| Net Income From Continuing Operations | $391,000,000 | $226,451,000 | $-61,286,000 | $-215,975,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-40,000,000 | $0 |
| Gain Loss On Investment Securities | - | - | $-4,585,000 | $-3,542,000 |
Fetched: 2026-07-15